started · updated
Viking Therapeutics reports BMI improvements in obesity trial
Viking Therapeutics has released new exploratory analysis from its Phase 2 VENTURE clinical trial regarding the obesity drug VK2735. The data, presented at the ObesityWeek annual meeting, indicates that 74 per cent of participants receiving the weekly subcutaneous injection improved by at least one body mass index (BMI) category after 13 weeks of treatment, compared to 15 per cent in the placebo group.
The analysis also highlighted improvements in cardiometabolic markers among treated participants. Those who saw a reduction in BMI category experienced greater decreases in waist circumference, fasting insulin, glucose, blood pressure, total cholesterol, triglycerides, and LDL-C compared to those whose BMI category remained unchanged.
VK2735 is a dual agonist of the GLP-1 and GIP receptors being developed in both subcutaneous and oral formulations. While earlier reports noted weight loss of 14.7 per cent at the highest dose, the company expects its pivotal injection studies to conclude in 2027.